• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clinical severity of human infections with avian influenza A(H7N9) virus, China, 2013/14

Eurosurveillance, Volume 19, Issue 49, 11 December 2014
Research articles
Clinical severity of human infections with avian influenza A(H7N9) virus, China, 2013/14
L Feng[SUP]1[/SUP][SUP],2[/SUP], J T Wu[SUP]2[/SUP][SUP],3[/SUP], X Liu[SUP]2[/SUP][SUP],4[/SUP], P Yang[SUP]2[/SUP][SUP],5[/SUP], T K Tsang[SUP]3[/SUP], H Jiang[SUP]1[/SUP], P Wu[SUP]3[/SUP], J Yang[SUP]1[/SUP], V J Fang[SUP]3[/SUP], Y Qin[SUP]1[/SUP], E H Lau[SUP]3[/SUP], M Li[SUP]1[/SUP], J Zheng[SUP]1[/SUP], Z Peng[SUP]1[/SUP], Y Xie[SUP]4[/SUP], Q Wang[SUP]5[/SUP], Z Li[SUP]1[/SUP], G M Leung[SUP]3[/SUP], G F Gao[SUP]6[/SUP][SUP],7[/SUP], H Yu ()[SUP]1[/SUP], B J Cowling[SUP]3[/SUP]
  • Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
  • These authors contributed equally to this work
  • School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China
  • Jiangxi Provincial Centre for Disease Control and Prevention, Nanchang, Jiangxi Province, China
  • Beijing Center for Disease Prevention and Control; and Beijing Research Center for Preventive Medicine, Beijing, China
  • CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Office of Director-General, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China

Citation style for this article: Feng L, Wu JT, Liu X, Yang P, Tsang TK, Jiang H, Wu P, Yang J, Fang VJ, Qin Y, Lau EH, Li M, Zheng J, Peng Z, Xie Y, Wang Q, Li Z, Leung GM, Gao GF, Yu H, Cowling BJ. Clinical severity of human infections with avian influenza A(H7N9) virus, China, 2013/14. Euro Surveill. 2014;19(49):pii=20984. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20984
Date of submission: 18 June 2014

[SIZE=+0]Assessing the severity of emerging infections is challenging because of potential biases in case ascertainment. The first human case of infection with influenza A(H7N9) virus was identified in China in March 2013; since then, the virus has caused two epidemic waves in the country. There were 134 laboratory-confirmed cases detected in the first epidemic wave from January to September 2013. In the second epidemic wave of human infections with avian influenza A(H7N9) virus in China from October 2013 to October 2014, we estimated that the risk of death among hospitalised cases of infection with influenza A(H7N9) virus was 48% (95% credibility interval: 42?54%), slightly higher than the corresponding risk in the first wave. Age-specific risks of death among hospitalised cases were also significantly higher in the second wave. Using data on symptomatic cases identified through national sentinel influenza-like illness surveillance, we estimated that the risk of death among symptomatic cases of infection with influenza A(H7N9) virus was 0.10% (95% credibility interval: 0.029?3.6%), which was similar to previous estimates for the first epidemic wave of human infections with influenza A(H7N9) virus in 2013. An increase in the risk of death among hospitalised cases in the second wave could be real because of changes in the virus, because of seasonal changes in host susceptibility to severe infection, or because of variation in treatment practices between hospitals, while the increase could be artefactual because of changes in ascertainment of cases in different areas at different times.[/SIZE]

http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20984
 
Back
Top Bottom